Edwards Lifesciences Corp Value Stock - Dividend - Research Selection
Edwards lifesciences
ISIN: US28176E1082 , WKN: 936853
Market price date:
Market price:
Market price:
Fundamental data and company key figures of the share
Annual reports in | |||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Key figures | |||||||||||||||||||||||||||||||||||||||||||||||||
Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
Net operating cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
Capital Expenditures | |||||||||||||||||||||||||||||||||||||||||||||||||
Free cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
Total Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
Liabilities & Shareholders equity | |||||||||||||||||||||||||||||||||||||||||||||||||
Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
Net income | |||||||||||||||||||||||||||||||||||||||||||||||||
Eps (diluted) | |||||||||||||||||||||||||||||||||||||||||||||||||
Diluted shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||
Net sales/revenue |
Do you want to do make a detailed fundamental analysis of this stock?
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
Description | Data |
---|---|
Symbol | |
Market Capitalization | USD |
Country | |
Indices | |
Sectors | |
Raw Data Source | |
Stock Split | |
Internet |
Description of the company
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient\'s heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient\'s physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,
NEWS
Where Will Edwards Lifesciences Stock Be In 4 Years?
2023-03-30
Edwards Lifesciences has had an impeccable record of steadily rising earnings for more than two decades. Read more about EW stock here.
UBS Initiates Coverage of Edwards Lifesciences (EW) with Neutral Recommendation
2023-03-30
Tracking David Rolfe's Wedgewood Partners Portfolio - Q4 2022 Update
2023-03-29
Wedgewood Partnersâ 13F portfolio value increased from $532M to $544M this quarter. Click here to see an update on the portfolio for Q4 2022.
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors despite daily gains
2023-03-29
Shares of Edwards Lifesciences Corp. advanced 1.43% to $81.64 Wednesday, on what proved to be an all-around great trading session for the stock market, with...
Tracking David Rolfe`s Wedgewood Partners Portfolio - Q4 2022 Update
2023-03-29
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Edwards Lifesciences initiated with a Neutral at UBS
2023-03-29
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Edwards Lifesciences: Solid, Not Spectacular
2023-03-28
Edwards Lifesciences Corporation saw solid underlying growth in 2022, held back by a strong dollar. Click here for our analysis of EW stock prospects for 2023.
Edwards Lifesciences Corp. stock falls Tuesday, underperforms market
2023-03-28
Shares of Edwards Lifesciences Corp. slumped 0.53% to $80.49 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the...
Here's Why You Should Retain Avantor (AVTR) Stock for Now
2023-03-28
Investors continue to be optimistic about Avantor's (AVTR) strong product portfolio.
NextGen's (NXGN) New Cloud-Based Solution to Improve Workflow
2023-03-28
NextGen's (NXGN) latest product is expected to simplify connectivity for healthcare providers, thereby solving clinical data exchange challenges.